Clinical trial NCT02811679: A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma
Official title: A Phase II Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Non-Hodgkin Lymphoma
Keywords: Lymphoma
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
Collaborators: name: Amgen
First posted: 2016-06-23
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This research study is studying Blinatumomab as a possible treatment for Indolent Non-Hodgkin Lymphoma (NHL).

Detailed description: This research study is a Phase II clinical trial. The overall purpose of this study is to determine if blinatumomab is safe and effective for treating adult subjects with relapsed or refractory indolent B cell NHL.

Blinatumomab will be infused causing T cells to recognize the Cancer and work against them. This approach has been FDA approved for acute lymphocytic leukemia but has not yet been approved for lymphoma.

Eligibility criteria: Inclusion Criteria:

* Subjects must have histologically determined B cell NHL that is relapsed or primary refractory after initial therapy.

  * Follicular Lymphoma of any grade
  * Marginal zone lymphoma (extranodal, nodal, or splenic). Patients with gastric MALT must have progressed after H. Pylori therapy and radiation. Patients with splenic MZL must have prior splenectomy.
* At least 1 prior line of chemoimmunotherapy if primary refractory or relapsed with in one year. Subjects who respond to initial therapy for greater than one year must have had at least 2 prior lines of therapy including one line with chemoimmunotherapy including an anti-CD20 monoclonal antibody
* Measurable disease that has not been previously irradiated on PET-CT of at least 1.5cm,
* Age ≥18 years.
* ECOG performance status ≤2 ( see Appendix A)
* Participants must have adequate organ and marrow function as defined below:

  * absolute neutrophil count ≥750/mcL
  * platelets ≥75,000/mcL
  * total bilirubin \< 2.0 x upper limit of normal (ULN)
  * AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal or 5 X ULN
  * if due to lymphoma infiltration
  * creatinine 2.0 X ULN OR
  * creatinine clearance ≥50 mL/min/1.73 m2 for participants with creatinine levels above 2.0 X ULN .
* Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

* Participants who have had chemotherapy within 3 weeks, rituximab or obinutuzumab within 4 weeks, or radioimmunotherapy within 6 weeks prior to entering the study, or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier. Subjects actively progressing within that window who have recovered from toxicities of prior therapy are also eligible.
* Autologous stem cell transplantation within 12 weeks prior to study entry
* Prior allogeneic transplant
* Therapeutic doses of corticosteroids within 14 days prior to study entry, defined as \>20mg/day pf prednisone, or equivalent. Topical and/or inhaled steroids are permitted.
* Participants who are receiving any other investigational agents.
* Participants with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to blinatumomab
* Subjects with known HIV infection
* Pregnant or lactating subjects.
* Chronic infection with hepatitis B or hepatitis C virus
* History of or current relevant CNS pathology such as epilepsy, seizure, paresis,aphasia, apoplexia, severe brain injuries, cerebellar disease, organic brain syndrome, psychosis
* Prior history of another malignancy (except for non-melanoma skin cancer, in situ cervical or breast cancer, or localized prostate cancer) unless disease free for at least one year and felt at low risk of relapse by treating physician.
* Uncontrolled intercurrent illness including, but not limited to, ongoing or uncontrolled systemic fungal, bacterial, viral, or other infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

Primary outcomes:
measure: Overall Response Rate (ORR)
timeFrame: at completion of treatment (6 months)
Secondary outcomes:
measure: Progression Free Survival
timeFrame: 5 years
measure: Time To Response Rate
timeFrame: 4 months
measure: Duration of Response
timeFrame: 5 years
measure: Rate Patients Are Discontinued From The Drug Due to Toxicity
timeFrame: 2 years
measure: Overall Survival
timeFrame: 5 years
Other outcomes:
Locations:
city: Boston
country: United States
facility: Massachusetts general Hospital
state: Massachusetts
Study officials:
affiliation: Massachusetts General Hospital
name: Jeffrey Barnes, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: